FDA clears Novartis’ new treatment for nAMD

Novartis has secured US regulatory approval for Beovu, the company’s latest therapy for neovascular age-related macular degeneration (nAMD), following the drug’s comparable results in head-to-head trials with Eylea. Read more

Macular disease research awarded $600,000

{{quote-a:r-w:400-I:2-Q:“Our latest round of grants are supporting exciting and innovative projects that will contribute to the body of evidence produced by Australian research.”-WHO:Julie Heraghty, Read more